Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease

Lipid Metabolism Laboratory, USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts.

The prevalence of abnormalities of lipoprotein cholesterol and apolipoproteins A-I and B and lipoprotein (a) [Lp(a)] was determined in 321 men (mean age 50 +/- 7 years) with angiographically documented coronary artery disease and compared with that in 901 control subjects from the Framingham Offspring Study (mean age 49 +/- 6 years) who were clinically free of coronary artery disease. After correction for sampling in hospital, beta-adrenergic medication use and effects of diet, patients had significantly higher cholesterol levels (224 +/- 53 vs. 214 +/- 36 mg/dl), triglycerides (189 +/- 95 vs. 141 +/- 104 mg/dl), low density lipoprotein (LDL) cholesterol (156 +/- 51 vs. 138 +/- 33 mg/dl), apolipoprotein B (131 +/- 37 vs. 108 +/- 33 mg/dl) and Lp(a) levels (19.9 +/- 19 vs. 14.9 +/- 17.5 mg/dl). They also had significantly lower high density lipoprotein (HDL) cholesterol (36 +/- 11 vs. 45 +/- 12 mg/dl) and apolipoprotein A-I levels (114 +/- 26 vs. 136 +/- 32 mg/dl) (all p less than 0.005). On the basis of Lipid Research Clinic 90th percentile values for triglycerides and LDL cholesterol and 10th percentile values for HDL cholesterol, the most frequent dyslipidemias were low HDL cholesterol alone (19.3% vs. 4.4%), elevated LDL cholesterol (12.1% vs. 9%), hypertriglyceridemia with low HDL cholesterol (9.7% vs. 4.2%), hypertriglyceridemia and elevated LDL cholesterol with low HDL cholesterol (3.4% vs. 0.2%) and Lp(a) excess (15.8% vs. 10%) in patients versus control subjects, respectively (p less than 0.05). Stepwise discriminant analysis indicates that smoking, hypertension, decreased apolipoprotein A-I, increased apolipoprotein B, increased Lp(a) and diabetes are all significant (p less than 0.05) factors in descending order of importance in distinguishing patients with coronary artery disease from normal control subjects. Not applying a correction for beta-adrenergic blocking agents, sampling bias and diet effects leads to a serious underestimation of the prevalence of LDL abnormalities and an overestimation of HDL abnormalities in patients with coronary artery disease. However, 35% of patients had a total cholesterol level less than 200 mg/dl after correction; of those patients, 73% had an HDL cholesterol level less than 35 mg/dl.

This article has been cited by other articles:

				E. M. deGoma, N. J. Leeper, and P. A. Heidenreich Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 49 - 55. [Abstract] [Full Text] [PDF]

				L. Berglund, M. Lefevre, H. N Ginsberg, P. M Kris-Etherton, P. J Elmer, P. W Stewart, A. Ershow, T. A Pearson, B. H Dennis, P. S Roheim, et al. Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1611 - 1620. [Abstract] [Full Text] [PDF]

				T. Kooistra, L. Verschuren, J. de Vries-van der Weij, W. Koenig, K. Toet, H.M.G. Princen, and R. Kleemann Fenofibrate Reduces Atherogenesis in ApoE*3Leiden Mice: Evidence for Multiple Antiatherogenic Effects Besides Lowering Plasma Cholesterol Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2322 - 2330. [Abstract] [Full Text] [PDF]

				A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 977 - 986. [Abstract] [Full Text] [PDF]

				E. Bruckert, R. Pamphile, F. McCoy, and P. Andre Defining the prevalence of low HDL-C in a European cohort of dyslipidaemic patients Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F23 - F26. [Abstract] [Full Text] [PDF]

				M. Y. Desai, A. Rodriguez, B. A. Wasserman, G. Gerstenblith, S. Agarwal, M. Kennedy, D. A Bluemke, and J. A.C. Lima Association of Cholesterol Subfractions and Carotid Lipid Core Measured by MRI Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): e110 - e111. [Full Text] [PDF]

				W. S. Tzou, P. S. Douglas, S. R. Srinivasan, W. Chen, G. Berenson, and J. H. Stein Advanced Lipoprotein Testing Does Not Improve Identification of Subclinical Atherosclerosis in Young Adults: The Bogalusa Heart Study Ann Intern Med, May 3, 2005; 142(9): 742 - 750. [Abstract] [Full Text] [PDF]

				S. Lamon-Fava and D. Micherone Regulation of apoA-I gene expression: mechanism of action of estrogen and genistein J. Lipid Res., January 1, 2004; 45(1): 106 - 112. [Abstract] [Full Text] [PDF]

				J.-F. Mauger, A. H Lichtenstein, L. M Ausman, S. M Jalbert, M. Jauhiainen, C. Ehnholm, and B. Lamarche Effect of different forms of dietary hydrogenated fats on LDL particle size Am. J. Clinical Nutrition, September 1, 2003; 78(3): 370 - 375. [Abstract] [Full Text] [PDF]

				B. E. Aouizerat, M. Kulkarni, D. Heilbron, D. Drown, S. Raskin, C. R. Pullinger, M. J. Malloy, and J. P. Kane Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids J. Lipid Res., June 1, 2003; 44(6): 1167 - 1173. [Abstract] [Full Text] [PDF]

				C.J. Packard Apolipoproteins: the new prognostic indicator? Eur. Heart J. Suppl., June 1, 2003; 5(suppl_D): D9 - D16. [Abstract] [PDF]

				M. Evans, A. Roberts, and A. Rees Pharmacological management of hyperlipidaemia The British Journal of Diabetes & Vascular Disease, May 1, 2003; 3(3): 204 - 210. [Abstract] [PDF]

				C. Parolini, G. Chiesa, Y. Zhu, T. Forte, S. Caligari, E. Gianazza, M. G. Sacco, C. R. Sirtori, and E. M. Rubin Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano. EVIDENCE OF APOA-IM IMPAIRED HEPATIC SECRETION J. Biol. Chem., February 7, 2003; 278(7): 4740 - 4746. [Abstract] [Full Text] [PDF]

				I. GOUNI-BERTHOLD and A. SACHINIDIS Does the coronary risk factor low density lipoprotein alter growth and signaling in vascular smooth muscle cells? FASEB J, October 1, 2002; 16(12): 1477 - 1487. [Abstract] [Full Text] [PDF]

				A. H. Xiang, S. P. Azen, T. A. Buchanan, L. J. Raffel, S. Tan, L.S.-C. Cheng, J. Diaz, E. Toscano, M. Quinonnes, C.R. Liu, et al. Heritability of Subclinical Atherosclerosis in Latino Families Ascertained Through a Hypertensive Parent Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 843 - 848. [Abstract] [Full Text] [PDF]

				J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF]

				S. J. Robins, D. Collins, J. T. Wittes, V. Papademetriou, P. C. Deedwania, E. J. Schaefer, J. R. McNamara, M. L. Kashyap, J. M. Hershman, L. F. Wexler, et al. Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events: VA-HIT: A Randomized Controlled Trial JAMA, March 28, 2001; 285(12): 1585 - 1591. [Abstract] [Full Text] [PDF]

				J Shepherd The statin era: in search of the ideal lipid regulating agent Heart, March 1, 2001; 85(3): 259 - 264. [Full Text]

				B. Haidar, S. Mott, B. Boucher, C. Y. Lee, M. Marcil, and J. Genest , Jr. Cellular cholesterol efflux is modulated by phospholipid-derived signaling molecules in familial HDL deficiency/Tangier disease fibroblasts J. Lipid Res., February 1, 2001; 42(2): 249 - 257. [Abstract] [Full Text]

				A. D. Sniderman, J. Bergeron, and J. Frohlich Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial Can. Med. Assoc. J., January 1, 2001; 164(1): 44 - 47. [Full Text] [PDF]

				A. Pedersen, M. W. Baumstark, P. Marckmann, H. Gylling, and B. Sandström An olive oil-rich diet results in higher concentrations of LDL cholesterol and a higher number of LDL subfraction particles than rapeseed oil and sunflower oil diets J. Lipid Res., December 1, 2000; 41(12): 1901 - 1911. [Abstract] [Full Text]

				J. E. R. van Lennep, H. T. Westerveld, H. W. O. R. van Lennep, A. H. Zwinderman, D. W. Erkelens, and E. E. van der Wall Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20(11): 2408 - 2413. [Abstract] [Full Text] [PDF]

				M. J. Zema Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study J. Am. Coll. Cardiol., March 1, 2000; 35(3): 640 - 646. [Abstract] [Full Text] [PDF]

				M. Nishino, M. J. Malloy, J. Naya-Vigne, J. Russell, J. P. Kane, and R. F. Redberg Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women J. Am. Coll. Cardiol., February 1, 2000; 35(2): 314 - 320. [Abstract] [Full Text] [PDF]

				J. M. Foody, J. A. Milberg, K. Robinson, G. L. Pearce, D. W. Jacobsen, and D. L. Sprecher Homocysteine and Lipoprotein(a) Interact to Increase CAD Risk in Young Men and Women Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 493 - 499. [Abstract] [Full Text] [PDF]

				B Jorgensen, S Simonsen, K Endresen, K Forfang, T Egeland, A.T Hostmark, and E Thaulow Luminal loss and restenosis after coronary angioplasty. The role of lipoproteins and lipids Eur. Heart J., October 1, 1999; 20(19): 1407 - 1414. [Abstract] [PDF]

				K. J. Harjai Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen Ann Intern Med, September 7, 1999; 131(5): 376 - 386. [Abstract] [Full Text] [PDF]

				L. J. Seman, C. DeLuca, J. L. Jenner, L. A. Cupples, J. R. McNamara, P. W.F. Wilson, W. P. Castelli, J. M. Ordovas, and E. J. Schaefer Lipoprotein(a)-Cholesterol and Coronary Heart Disease in the Framingham Heart Study Clin. Chem., July 1, 1999; 45(7): 1039 - 1046. [Abstract] [Full Text] [PDF]

				A. M. Gotto Jr Prognostic and Therapeutic Significance of Low Levels of High-Density Lipoprotein Cholesterol: Current Perspectives Arch Intern Med, May 24, 1999; 159(10): 1038 - 1040. [Full Text] [PDF]

				C. R. Harper and T. A. Jacobson New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol Arch Intern Med, May 24, 1999; 159(10): 1049 - 1057. [Abstract] [Full Text] [PDF]

				S. J. Lewis, L. A. Moye, F. M. Sacks, D. E. Johnstone, G. Timmis, J. Mitchell, M. Limacher, S. Kell, S. P. Glasser, J. Grant, et al. Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial Ann Intern Med, November 1, 1998; 129(9): 681 - 689. [Abstract] [Full Text]

				F. Ribichini, G. Steffenino, A. Dellavalle, A. Vado, V. Ferrero, T. Camilla, S. Giubergia, and E. Uslenghi Plasma Lipoprotein(a) Is Not a Predictor for Restenosis After Elective High-Pressure Coronary Stenting Circulation, September 22, 1998; 98(12): 1172 - 1177. [Abstract] [Full Text] [PDF]

				B. Lamarche, A. Tchernof, P. Mauriege, B. Cantin, G. R. Dagenais, P. J. Lupien, and J.-P. Despres Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size as Risk Factors for Ischemic Heart Disease JAMA, June 24, 1998; 279(24): 1955 - 1961. [Abstract] [Full Text] [PDF]

				J. R. McNamara, P. K. Shah, K. Nakajima, L. A. Cupples, P. W. F. Wilson, J. M. Ordovas, and E. J. Schaefer Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study Clin. Chem., June 1, 1998; 44(6): 1224 - 1232. [Abstract] [Full Text] [PDF]

				P. N. Hopkins, L. L. Wu, S. C. Hunt, B. C. James, G. M. Vincent, and R. R. Williams Lipoprotein(a) Interactions With Lipid and Nonlipid Risk Factors in Early Familial Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2783 - 2792. [Abstract] [Full Text]

				B. Lamarche, A. Tchernof, S. Moorjani, B. Cantin, G. R. Dagenais, P. J. Lupien, and J.-P. Despres Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men: Prospective Results From the Quebec Cardiovascular Study Circulation, January 7, 1997; 95(1): 69 - 75. [Abstract] [Full Text]

				F. M. Sacks, M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford, T. G. Cole, L. Brown, J. W. Warnica, J. M. O. Arnold, C.-C. Wun, et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels N. Engl. J. Med., October 3, 1996; 335(14): 1001 - 1009. [Abstract] [Full Text] [PDF]

				S. Sunayama, H. Daida, H. Mokuno, H. Miyano, H. Yokoi, Y. J. Lee, H. Sakurai, and H. Yamaguchi Lack of Increased Coronary Atherosclerotic Risk Due to Elevated Lipoprotein(a) in Women >=55 Years of Age Circulation, September 15, 1996; 94(6): 1263 - 1268. [Abstract] [Full Text]

				B. Lamarche, S. Moorjani, P. J. Lupien, B. Cantin, P.-M. Bernard, G. R. Dagenais, and J.-P. Despres Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Quebec Cardiovascular Study Circulation, August 1, 1996; 94(3): 273 - 278. [Abstract] [Full Text]

				J. Ferrieres, J. Lambert, S. Lussier-Cacan, and J. Davignon Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation Circulation, August 1, 1995; 92(3): 290 - 295. [Abstract] [Full Text]

				R. J. Havel and E. Rapaport Management of Primary Hyperlipidemia N. Engl. J. Med., June 1, 1995; 332(22): 1491 - 1498. [Full Text] [PDF]

				D. J. Rader, J. M. Hoeg, and H. B. Brewer Quantitation of Plasma Apolipoproteins in the Primary and Secondary Prevention of Coronary Artery Disease Ann Intern Med, June 15, 1994; 120(12): 1012 - 1025. [Abstract] [Full Text]